Loyal portfolio

Ignota Labs logo

Ignota Labs

Health · United Kingdom

Follow OnUnited KingdomINSEAD
Sam WindsorL

Sam Windsor · Layla Hosseini-Gerami

About Ignota Labs

Ignota Labs is an AI drug turnaround company. They use cutting-edge explainable AI to understand toxic liabilities of drugs which have failed during development. They use these novel insights to acquire those drugs with hidden potential, fix the liability and sell them on, bringing new hope to patients.

Visit website

In the news

  • Nov 16

    Ignota Labs attends London Life Sciences Week as Tim Sparey and Omar Alkhatib represent the company.

    View on LinkedIn
  • Nov 13

    Ignota Labs shares its co-founder’s strategies for using agentic AI to analyze and refine shelved drugs at ACT 2026.

    View on LinkedIn
  • Nov 10

    Ignota Labs appoints Kelly Gray chief operating officer after her role as senior alliances manager.

    View on LinkedIn
  • Nov 9

    Ignota Labs’ leader reflects on presenting “The Second Chance,” a TEDAI Vienna talk about using AI to recover value from failed drugs.

    View on LinkedIn
  • Nov 4

    Ignota Labs seeks shelved drug assets, especially those with safety challenges, for acquisition and partnering.

    View on LinkedIn
  • Oct 28

    Ignota Labs sends co-founder Layla Hosseini-Gerami to speak at TEDAI Vienna about using AI to revive failed drug candidates.

    View on LinkedIn

Founders

  • Sam Windsor

    Sam Windsor

  • L

    Layla Hosseini-Gerami

Details

Stage
Follow On
Sector
Health
Country
United Kingdom
Region
United Kingdom
Source
INSEAD